Policy & Regulation
Cirius Therapeutics Presents Interim Data from Phase 2b Clinical Study of MSDC-0602K
15 April 2019 - - US-based Cirius Therapeutics has presented positive results from an interim analysis of exploratory endpoints from the EMMINENCE trial, its ongoing Phase 2b clinical trial evaluating MSDC-0602K in 402 patients diagnosed with non-alcoholic steatohepatitis with fibrosis, at The International Liver Congress 2019, occurring in Vienna, Austria, the company said.

The interim analysis, which was conducted in the first 328 patients to reach their six-month follow-up visit, demonstrated that patients treated with MSDC-0602K had significant improvements from baseline in measures of liver function and insulin resistance at six months.

Key findings from the interim analysis include improvements in liver enzymes, with placebo-corrected reductions at 6 months of 14.3 U/L (p